News
CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and accompanying heart failure with preserved ejection fraction (HFpEF ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback